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Introduction
Liver fibrosis is the common consequence of chronic
liver injury of any etiology (1). Advanced liver fibrosis dis-
rupts the normal liver architecture, causing hepatocel-
lular dysfunction and portal hypertension. Unfortu-
nately, no effective hepatic antifibrotic therapies are
available. The hepatic stellate cells (HSCs) are a major
fibrogenic cell type in the liver (2). Following injury,
HSCs are activated to myofibroblast-like cells, which
promote collagen deposition. Recent evidence indicates
that angiotensin II (Ang II) may be an important media-
tor in liver fibrosis. Serum Ang II levels are frequently ele-
vated in patients with cirrhosis, and a local renin-
angiotensin system is upregulated in experimental
hepatic fibrogenesis (3, 4). Patients with chronic hepati-
tis C and a genetic polymorphism associated with
increased Ang II synthesis have been reported to develop
more severe fibrosis (5). Moreover, inhibition of Ang II
synthesis and/or the blockade of Ang II type 1 (AT1)
receptors markedly attenuate inflammation and fibro-
sis in experimental models of chronic liver injury (6–10).
However, the cellular and molecular mechanisms under-
lying the apparent fibrogenic effect of Ang II on the liver
are unknown. In other tissues, Ang II is locally synthe-
sized during tissue remodeling and exerts an array of bio-
logical actions on resident myofibroblasts (11). In the
injured liver, activated HSCs are potential targets for 
Ang II, since they express functional AT1 receptors (12).
Reactive oxygen species (ROS) play an important role
in hepatic fibrosis (13). Increased ROS and resulting
oxidative stress are commonly detected in livers from
patients with alcohol abuse, hepatitis C virus infection,
iron overload, or chronic cholestasis, as well as in most
types of experimental liver fibrogenesis (14–18). More-
over, antioxidant agents attenuate hepatic fibrosis in
rodents and may exert beneficial effects in patients
with chronic liver diseases (19, 20). The cellular origin
and molecular mechanisms underlying the fibrogenic
effect of ROS are under investigation. CYP2E1-derived
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ROS from damaged hepatocytes can induce phenotyp-
ic activation, proliferation, and increased collagen syn-
thesis in cultured HSCs (21–23). An alternative source
of ROS in the injured liver is NADPH oxidase. This
enzyme generates large amounts of superoxide anions
in phagocytic cells and plays a key role in immune
defense (24). Recently, a nonphagocytic form of
NADPH oxidase has been demonstrated in vascular cell
types (25). Like the phagocytic respiratory burst
NADPH oxidase, nonphagocytic NADPH oxidase
reduces molecular oxygen to generate superoxide,
which is in turn converted to hydrogen peroxide. How-
ever, unlike the phagocytic type, the NADPH oxidases
present in blood vessels are constitutively active, pro-
ducing relatively low levels of ROS under basal condi-
tions and generating higher levels of oxidants in
response to cytokines such as Ang II. Increased ROS
production results in the stimulation of redox-sensitive
intracellular pathways (26, 27). Both the phagocytic
and nonphagocytic oxidases are multimeric enzymes
composed of plasma membrane–associated proteins as
well as cytosolic factors (28). In the phagocytic NADPH
oxidase, the plasma membrane–associated proteins
gp91phox and p22phox compose the flavocytochrome
b558 complex, which forms the catalytic subunit of the
oxidase. Cytosolic factors, which include p47phox, are
phosphorylated by agonists and translocate to the cell
membrane to form the active NADPH oxidase. In
VSMCs, gp91phox is barely expressed, suggesting that
other subunits are present to form catalytically active
NADPH oxidase. Recently, several smooth muscle cell
homologs of gp91phox, termed Nox (nonphagocytic oxi-
dase), have been identified (29).
In alcohol-induced liver disease, NADPH oxidase
appears to be a key oxidant, as mice lacking p47phox, a
cytoplasmic component required for enzymatic activa-
tion, do not develop alcoholic liver disease (30). More-
over, inhibition of NADPH by diphenylene iodonium
(DPI) attenuates alcoholic liver disease (31). Kupffer
cells highly express phagocytic NADPH oxidase and
generate high amounts of ROS during early liver injury
(32). However, it is unknown whether other non-
parenchymal cells such as HSCs express NADPH oxi-
dase and whether this enzyme regulates the response to
fibrogenic cytokines such as Ang II. In this study, we
demonstrate that activated HSCs express NADPH oxi-
dase to generate ROS, which mediate the multiple
fibrogenic actions of Ang II. Moreover, mice lacking a
functional NADPH oxidase are resistant to liver fibro-
sis. These data indicate that activation of NADPH oxi-
dase plays an important role in the wound-healing
response to chronic liver injury.
Methods
Chemicals. Ang II, N-acetylcysteine (NAC), DPI, and
PD123319 were purchased from Sigma-Aldrich (St.
Louis, Missouri, USA). Losartan was kindly provided by
Merck & Co. (Rahway, New Jersey, USA). 2′,7′-Dichloro-
fluorescein diacetate (DCFDA) was obtained from
Molecular Probes Inc. (Eugene, Oregon, USA).
PD98059, SB203580, and LY294002 were purchased
from Calbiochem-Novabiochem Corp. (La Jolla, Cali-
fornia, USA). SP600125 was obtained from Celgene
Corp. (San Diego, California, USA).
Animals and treatments. NADPH oxidase–deficient
(p47phox–/–) C57BL/6 mice, which lack a critical cytoso-
lic component required for assembly of an active
NADPH oxidase complex, were expanded in parallel
with parental inbred WT mice (30, 33). Two-month-
old female mice were used for HSC isolations and for
experimental liver fibrosis. Liver fibrosis was induced
by bile duct ligation. Briefly, mice were anesthetized
with sodium pentobarbital. After midline laparotomy,
the common bile duct was doubly ligated with 4-0 silk
and transected between the two ligations. Sham oper-
ation was performed similarly except that the bile duct
was not ligated and transected. Mice were randomized
to undergo bile duct ligation or sham operation. Ten
mice were used in each group. All animals were sacri-
ficed 2 weeks after surgery, and blood and liver sam-
ples were obtained. Mice were housed in a pathogen-
free barrier facility accredited by the Association for
the Accreditation and Assessment of Laboratory Ani-
mal Care. All procedures were approved by the Investi-
gation and Ethics Committee and Institutional Ani-
mal Care and Use Committee of the University of
North Carolina at Chapel Hill.
Cell culture. Human HSCs were isolated from surgical
specimens of normal human livers as previously
described (34). After isolation, cells were seeded on
uncoated plastic tissue-culture dishes and cultured in
DMEM (GIBCO BRL; Life Technologies Inc., Grand
Island, New York, USA) supplemented with 15% FCS.
Experiments were performed in five independent prepa-
rations between passages 2 and 5. Rat HSCs were isolat-
ed from male Sprague-Dawley rats (>400 g) as previous-
ly described (35). Mouse HSCs were isolated from WT
(C57BL/6) and p47phox–/– mice as previously described
(36). Both rat and mouse HSCs were cultured in DMEM
supplemented with 10% FCS. Rat hepatocytes were 
isolated from male Sprague-Dawley rats (250 g) as
described previously (37). Hepatocytes were plated on
dishes coated with rat type I collagen in Waymouth’s
medium (GIBCO BRL; Life Technologies Inc.) con-
taining 10% FCS, 0.1 mmol/l insulin, and 0.1 mmol/l
dexamethasone. After 2 hours, the cultures were
washed with PBS and changed to RPMI medium
(GIBCO BRL) containing 0.1 mmol/l insulin, 2 mmol/l
L-glutamine, 5 mg/ml transferrin, 1 nmol/l selenium,
and 1.52 µmol/l FFAs.
Serum biochemical measurements. Serum alanine amino-
transferase (ALT), aspartate aminotransferase (AST),
and bilirubin levels were measured using standard
enzymatic procedures by the Pathology Department of
the University of North Carolina at Chapel Hill.
Histochemical studies. Paraffin-embedded sections were
stained with H&E and Masson’s trichrome. For
immunohistochemical analysis, sections were deparaf-
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finized, rehydrated, and stained using the DAKO EnVi-
sion system protocol (DAKO Corp., Carpinteria, Cali-
fornia, USA). Sections were incubated with anti–
smooth muscle α-actin (1:1,000; DAKO Corp.) and
anti–TGF-β1 (1:1,000; Santa Cruz Biotechnology Inc.,
Santa Cruz, California, USA) for 30 minutes at room
temperature. As negative controls, all specimens were
incubated with an isotype-matched control antibody.
The area of positive staining was measured using a
Macintosh-based morphometric analysis system
(Apple Computer Inc., Brea, California, USA) with
MetaMorph software (Universal Imaging Corp., Down-
ingtown, Pennsylvania, USA).
Quantification of hepatic collagen content. Collagen con-
tent was assessed both by morphometric analysis of Sir-
ius red staining of liver sections and by hydroxyproline
concentration. The area of positive Sirius red staining
was measured using MetaMorph software. Hydroxy-
proline content was quantified colorimetrically from
0.2-g liver samples. Tissue was homogenized in 6N HCl
and hydrolyzed at 110°C for 16 hours. The hydrolysate
was filtered, aliquots were evaporated under vacuum,
and the sediment was redissolved in 50% isopropanol.
Samples were then incubated in a solution containing
0.84% chloramine-T 42 mM sodium acetate, 2.6 mM
citric acid, and 39.5% (vol/vol) isopropanol (pH 6.0) for
10 minutes at room temperature. Next, samples were
incubated in a solution containing 0.248 g p-dimethy-
laminobenzaldehyde dissolved in 0.27 ml of 60% per-
chloric acid and 0.73 ml of isopropanol for 90 minutes
at 50°C. Hydroxyproline content was quantified pho-
tometrically at 558 nm. The results were expressed as
micrograms hydroxyproline per gram liver.
Measurement of intracellular ROS. Cells cultured in 24-
well plates were loaded with the redox-sensitive dye
DCFDA (10 µM) for 20 minutes at 37°C. Cells were
then rinsed twice with DMEM and stimulated with
agonist. DCFDA fluorescence was detected at excita-
tion and emission wavelengths of 488 nm and 520 nm,
respectively. ROS formation was measured using a
multiwell fluorescence scanner (CytoFluor 2300; Mil-
lipore Corp., Bedford, Massachusetts, USA) and a Zeiss
LSM 510 confocal laser-scanning microscope (Carl
Zeiss, Oberkochen, Germany).
RT-PCR. The presence of p47phox mRNA in human
HSCs was investigated by semiquantitative RT-PCR.
Total RNA was extracted from cultured cells and normal
human livers using TRIzol reagent (Invitrogen Corp.,
Carlsbad, California, USA). One microgram of RNA was
reverse-transcribed using dT15-oligonucleotide and
Moloney murine leukemia virus reverse transcriptase
(Perkin-Elmer Applied Biosystems, Foster City, Califor-
nia, USA) in 25 µl of volume. Specific primers were
designed as follows: p47phox: sense 5′-GTACCCAG-
CCAGCACTATG-3′, antisense 5′-GTCTGGTTGTCTGTG-
GGGAG-3′; gp91phox: sense 5′-GAATGGGGAAAAATAAAG-
GAATG-3′, antisense 5′-ACCCTTCTTCATCTGTAGC-3′;
Nox1: sense 5′-CCAGGATTGAAGTGGATGGT-3′, antisense
5′-CGGTGAGGAAGAGACGGTAG-3′. Reactions were per-
formed using 1 µM primers in a 50-µl total volume con-
taining 1.5 mM MgCl2, 50 mM KCl, and 10 mM Tris (pH
8.3). PCR amplification was carried out by 30 cycles of
denaturation (96°C, 30 seconds), annealing (62°C, 45
seconds), and extension (72°C, 20 seconds). PCR prod-
ucts were analyzed by electrophoresis in a 1.5% agarose
gel. GAPDH amplification was used to demonstrate
equal RNA load.
RNase protection assay. Rat-liver total RNA was
obtained using the TRIzol. RNase protection assay for
procollagen α1(I) was performed as previously
described (35). Ten micrograms of total RNA was
hybridized with 5.105 cpm of riboprobe. Riboprobes
were derived from the 375-bp PstI-AvaI fragment from
rat procollagen α1(I) cDNA, cloned into HincII-PstI
sites of the pGEM 3zf+ vector, and from the plasmid
pTRI-GAPDH-rat (Ambion Inc., Austin, Texas, USA).
Twenty micrograms of yeast transfer RNA (tRNA) was
hybridized as a negative control. The protected ribo-
probes were visualized by autoradiography and quan-
titated by PhosphorImager analysis (Molecular
Dynamics, Sunnyvale, California, USA).
Western blotting. Whole-cell extracts were obtained in
Triton lysis buffer, and liver extracts were obtained in
modified radioimmunoprecipitation buffer as previous-
ly described (37). Western blotting was performed under
standard conditions. Antibodies against 4-hydroxy-2-
nonenal (HNE; Alpha Diagnostic International Inc., San
Antonio, Texas, USA), phosphoserine (Zymed Laborato-
ries Inc., San Francisco, California, USA), phospho-ERK,
phospho–p38 MAPK, phospho-AKT (Cell Signaling
Technology Inc., Beverly, Massachusetts, USA), heme
oxygenase-1, α-tubulin, inhibitor of κB-α (IκBα), p47phox,
and phospho-Jun (Santa Cruz Biotechnology Inc.) were
used at a dilution of 1:1,000. For detection of collagen I
secretion, cells were cultured in 100-mm culture dishes
(106 cells per dish). Cells were stimulated with agonists
for 20 hours, and 4 ml of cell media were precipitated
with 0.76 g of sodium sulfite at 4°C for 3 hours and then
centrifuged at 10,000 g for 30 minutes. Pellets were resus-
pended in 0.5 M acetic acid, and 40-µl aliquots were sub-
jected to electrophoresis on a 7.5% acrylamide gel. After
blotting, membranes were probed with anti–human col-
lagen type I antibody (1:1,000; BIODESIGN Interna-
tional, Saco, Maine, USA), which recognizes the procol-
lagen 1(I) chain, the mature 1(I) chain, and the
heterotrimer of type I collagen. Prior to electrophoresis,
some samples were digested at room temperature for
30 minutes with pepsin (1,000 U; Sigma) at pH 2.5 or
with bacterial collagenase (7.5 U; Roche Molecular Bio-
chemicals, Indianapolis, Indiana, USA) as controls for
antibody specificity. Treatment with collagenase result-
ed in complete loss of signal, whereas treatment with
pepsin resulted in reduction of the molecular mass from
170 to 120 kDa (not shown).
Kinase assays. Kinase reactions were performed as pre-
viously described (38). For IκB kinase (IKK) assay, 300 µg
proteins were immunoprecipitated with 2 µl anti-IKKγ
(a gift from F. Mercurio, Celgene Corp.) for 2 hours 
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followed by 20 µl protein A/G-agarose (Santa Cruz
Biotechnology Inc.) for 1 hour. Kinase reaction was per-
formed using glutathione-S-transferase–IκB (GST-IκB)
as a substrate (a gift from H. Sakurai, Tanabe Seiyaku
Co., Osaka, Japan). For the JNK assay, 50 µg protein was
incubated with 1 µl GST–c-Jun bound to GST beads
washed, and subjected to a kinase reaction. For the
extracellular signal–regulated kinase (ERK) assay, 200
µg proteins were immunoprecipitated with 2 µl
anti–ERK-2 (Santa Cruz Biotechnology Inc.) for 2 hours
followed by 20 µl protein A/G-agarose for 1 hour. The
kinase reaction was performed using myelinic basic pro-
tein (Sigma) as a substrate. For the p38 MAPK assay,
250 µg proteins were immunoprecipitated with 5 µl of
immobilized anti-p38 antibody (Santa Cruz Biotech-
nology Inc.), and the kinase reaction was performed
using myelinic basic protein as a substrate. For the AKT
assay, 250 µg protein was immunoprecipitated with 4
µl of immobilized AKT antibody (Santa Cruz Biotech-
nology Inc.). The kinase reaction was performed using
a GSK-3 fusion protein as a substrate.
Electrophoretic mobility shift assay. Cell nuclear proteins
were extracted as described previously (39). Eight micro-
grams of nuclear proteins were incubated with 100 pg
of a 32P-labeled probe containing the AP-1 consensus
site (5′-GTAAAGCATGAGTCAGACACCTC-3′) in buffer
containing 10 mM HEPES (pH 7.8), 2 mM MgCl2, 50
mM KCl, 1 mM DTT, 0.1 mM EDTA, and 20% glycerol
in the presence of single-stranded oligonucleotide (25
µg/ml) and Poly(dI-dC) (Amersham Biosciences Corp.,
Piscataway, New Jersey, USA) (25 µg/ml) for 20 minutes
at room temperature. For competition assay, one sam-
ple was incubated with 10 ng unlabeled probe.
Preparation of RNA and cDNA microarrays. Activated
human HSCs were cultured in 150-mm dishes until
confluent. Cells were serum-starved overnight and
then stimulated with buffer or agonists for 24 hours.
Total RNA was isolated using TRIzol. Thirty micro-
grams of RNA from each sample was used to prepare
cRNA probes as described in the manufacturer’s pro-
tocol (Affymetrix Inc., Santa Clara, California, USA).
Probes were hybridized to gene chips (Affymetrix Inc.
Figure 1
Ang II increases ROS formation and lipid peroxidation in human HSCs via NADPH activity. (a) HSCs were loaded with DCFDA (10 mM)
and studied with laser confocal microscopy. Ang II (10–8 M) markedly increased cell fluorescence. This effect was prevented by DPI (10–6 M).
(b) Quantification of fluorescent changes in DCFDA-loaded cells using a fluorometer at excitation and emission wavelengths of 488 nm and
520 nm, respectively. Ang II increased cell fluorescence that was blocked by DPI and losartan (10–7 M). Data are representative of three inde-
pendent experiments. (c) Expression of mRNA encoding p47phox, gp91phox, and Nox1 in human HSCs, as assessed by RT-PCR. Quiescent
HSCs (2 days in culture after isolation from a normal human liver), human HSCs activated in culture (cells isolated from normal livers and
cultured for 14 days), and HSCs activated in vivo (2 days in culture after isolation from a human cirrhotic liver) were studied. GAPDH was
amplified to demonstrate equal loading. (d) Ang II phosphorylates p47phox in human HSCs. Cells were treated with Ang II for 5 minutes, and
cell extracts were immunoprecipitated with anti-p47phox antibody and blotted with either anti-p47phox antibody or anti-phosphoserine 
(P-serine) antibody. (e) Ang II induces HNE protein adducts and upregulates heme oxygenase-1 (HO-1) protein expression in HSCs. HSCs
were stimulated for 12 hours with Ang II, and cell extracts were blotted with anti-HNE and anti–heme oxygenase-1 antibodies. Cells were
preincubated with buffer, DPI, or losartan before addition of Ang II. α-Tubulin was used to demonstrate equal loading.
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HGU95AV2; 12,000 genes). Changes in gene expres-
sion were assessed using Affymetrix Microarray Suite
(version 4.0; Affymetrix Inc.). Microarray experiments
were repeated three times with similar results. Two
independent hybridizations were technically optimal,
and the results shown are the mean of these two exper-
iments. Control experiments (GeneChip Test3 Array;
Affymetrix Inc.) were performed to ensure the integri-
ty of the cRNA probes.
DNA synthesis. DNA synthesis was estimated as the
amount of methyl-3H-thymidine (ICN Biomedicals Inc.,
Irvine, California, USA) incorporated into trichloro-
acetic-precipitable material (36).
Migration studies. Cell migration was assessed both
with a modified Boyden chamber and by an in vitro
wound-healing assay. For the first approach, 13-mm
filters of 8 µm porosity (Whatman Inc., Clifton, New
Jersey, USA) were coated with 20 µg/ml collagen I at
37°C for 30–60 minutes. The filters were then placed
between the upper and lower chambers of the Boyden
system (NeuroProbe Inc., Gaithersburg, Maryland,
USA). The lower chamber was filled with serum-free
medium (205 µl) containing the substances to be test-
ed. Serum-starved HSCs were trypsinized and placed
into the upper chamber (105 cells/ml). After 6 hours
of incubation at 37°C, cells adhering to the upper side
of the filter were removed with a cotton swab. The fil-
ters were then fixed in 96% methanol for 2 minutes
and then stained with Harris’ hematoxylin solution
for 1–2 minutes. Cells migrated to the lower side of
the filter were counted by a light microscope at six to
ten randomly chosen high-power fields. For the
wound-healing assay, HSCs were cultured until con-
fluence on 40-mm-diameter glass coverslips coated
with 20 µg/ml collagen I. Cells were serum-starved for
24 hours, and a 2-mm-wide linear wound was cleared.
Cells were then incubated with agonists for 20 hours.
Cells migrating into the wound were detected using a
phase-contrast microscope.
Determination of TGF-β1, IL-8, and monocyte chemoat-
tractant protein-1 levels by ELISA. For TGF-β1, rat HSCs
were cultured in six-well plates at a density of 4.105 cells
per well for 4 days. Medium was then removed and cells
challenged with agonists for 20 hours. Supernatants
were collected, and an ELISA for TGF-β1 (R&D Systems
Inc., Minneapolis, Minnesota, USA) was performed. For
detection of bioactive TGF-β1, supernatants were acid-
ified for 20 minutes at room temperature with 1N HCl
(1:50 vol/vol) and then neutralized with 1N NaOH (1:50
vol/vol) before TGF-β1 determination. For chemokine
release, human HSCs were cultured in six-well plates at
a density of 4.105 cells per well for 24 hours. Medium
was removed, and cells were incubated in serum-free
medium for 24 hours in the presence of agonists.
Supernatants were collected, and a sandwich ELISA for
human IL-8 and monocyte chemoattractant protein-1
(MCP-1) was performed. Results are expressed as fold
increase with respect to untreated cells.
Statistical analysis. Results are expressed as mean ± SEM.
For Western blot, electrophoretic mobility shift assays,
and kinase assays quantitation was carried out by scan-
ning of the intensity of the signals with NIH Image 1.63
software (NIH, Bethesda, Maryland, USA). The results
were analyzed using the paired or unpaired Student’s 
t test or the Newman-Keuls test. A P value of less than
0.05 was considered statistically significant.
Figure 2
Ang II stimulates intracellular signaling pathways in human HSCs in
a redox-sensitive manner. (a) Ang II stimulates phosphorylation of
MAPK proteins and AKT in a redox-sensitive manner. HSCs prein-
cubated with buffer, losartan (10–7 M), the AT2 receptor antagonist
PD123319 (10–7 M), NAC (10–4 M), or DPI (10–6 M) were stimulat-
ed for 10 minutes with Ang II (10–8 M). Twenty-five micrograms of
cell extracts were subjected to Western blotting using anti–phos-
pho–ERK-2, anti–phospho–c-Jun, and anti–phospho–p38 MAPK
antibodies. Anti–α-tubulin antibody was used to demonstrate equal
protein loading. ERK-2, JNK, AKT, and p38 MAPK activities were
assessed by specific kinase assays (see Methods). Cells were stimu-
lated for 10 minutes with Ang II (10–8 M) in the presence or absence
of losartan, PD123319, NAC, and DPI. (b) Ang II does not induce
phosphorylation of STAT1 and STAT3. Cells were stimulated for 10
minutes with Ang II (10–8 M) or IFN-γ (100 U/ml), and 25 µg of cell
extracts were subjected to Western blotting using anti–phospho-
STAT1 and -STAT3 antibodies. Anti–α-tubulin antibody was used
to demonstrate equal protein loading. (c) Ang II activates AP-1 DNA
binding in human HSCs. Stimulation with Ang II (10–8 M) for 2
hours increased AP-1 binding, as assessed by electrophoretic mobil-
ity shift assay. This effect was prevented by losartan (10–7 M), NAC
(10–5 M), and DPI (10–6 M), but not by PD123319 (10–7 M). Num-
bers underneath the gel represent fold expression compared with
cells treated with buffer.
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Results
Ang II induces ROS formation and lipid peroxidation in
human HSCs through NADPH oxidase activation. Ang II
(10–8 M) induced a marked increase in ROS formation
in activated human HSCs, as measured by DCFDA flu-
orescence (Figure 1, a and b). This effect was blocked by
the AT1 receptor antagonist losartan (10–7 M), but not
by the AT2 receptor antagonist PD123319 (10–8 M) (not
shown). Incubation of cells with DPI (10–6 M), a specif-
ic NADPH oxidase inhibitor, markedly blunted ROS
formation after Ang II exposure. To confirm that Ang II
activates NADPH oxidase in human HSCs, we investi-
gated the expression of key enzymatic components (Fig-
ure 1c). mRNAs for the cytoplasmic factor p47phox and
the cell membrane proteins gp91phox and Nox1 were not
detected in quiescent HSCs, while they were highly
expressed following cell activation in culture and in cells
freshly isolated from patients with liver fibrosis. In con-
trast, gp91phox was only expressed in culture-activated
HSCs. These data indicate that HSCs activated in vivo
Table 1
DPI prevents Ang II–induced changes in gene expression in human activated HSCs
Accession no. Gene name Ang IIA DPI + Ang IIA Accession no. Gene name Ang IIA DPI + Ang IIA
Extracellular matrix Cell cycle/Differentiation/Apoptosis
M21337 Collagen α6(IV) 13.1 1.0 U49260 Mortalin 6.0 1.5
X05232 Stromelysin 7.2 1.1 F062739 FRAT2 4.2 1.3
M20776 Collagen α1(VI) 7.0 2.6 X67325 p27 2.0 0.9
M12272 Collagen α4(VI) 6.8 2.4 D88357 CDC2 4.5 1.1
U54804 Hyaluronan synthase 2 7.3 1.4 L42450 p27kip1 4.0 1.1
AB002631 Collectin 34 4.2 0.6 X00088 Histone H2b 3.0 1.1
M12272 PAI-2 3.0 1.2 AJ000186 MAD2 2.3 0.9
AF0908641 CD44 2.4 1.1 AF040963 MAD4 2.1 1.4
U69263 Matrilin 2 2.5 1.0 M14949 R-ras 2.4 0.9
U58331 Sarcoglycan 2.0 0.6 U22376 c-myb 2.7 1.0
U03877 Fibrillin-like (S1-5) 2.1 0.8 Vasoactive substances/Neurotransmitters
Y12779 Enamelysin 4.5 0.9 AF004021 PGF2α receptor 4.3 0.9
Z74615 Collagen α1(I) 2.1 1.2 D13168 Endothelin B receptor 7.0 0.7
U41068 Collagen α2(XI) 3.4 0.7 M88714 Bradykinin receptor-2 2.1 1.9
Growth factors/Cytokines D14874 Adrenomedullin 2.0 0.7
M65062 IGF-binding protein-5 8.9 0.8 AF056085 GABA-B receptor 23.5 3.2
M59964 Stem cell factor 6.3 1.1 X68487 A2b adenosine receptor 2.0 0.7
M12272 Angiopoietin-1 4.9 0.9 U08989 Glutamate transporter 2.0 0.5
AB000734 TIP3 8.1 2.3 U28049 Thromboxane B2 7.0 2.1
M12272 HGF 4.6 2.5 Signaling
M19154 TGF-β2 2.5 1.1 L40904 PPARγ 2.0 1.6
X52599 β nerve growth factor 4.4 2.5 Y07867 Pirin 10.2 1.0
X94216 VEGF-C 2.6 1.0 L19871 ATF3 4.4 1.2
AF054598 TGF-β1 receptor 2.6 2.3 Y18207 Protein phosphatase 1 2.5 1.4
M60828 KGF 2.4 0.9 M90696 Cathepsin S 5.7 3.7
X00588 EGF receptor 2.1 1.3 U20816 NF-κB2 3.0 1.5
HSU66198 FHF-2 5.3 1.2 AJ223957 ARNO3 4.0 9.8
Inflammation/Immunity M20560 Lipocortin-III 2.1 0.9
M21121 RANTES 6.0 0.9 D50840 Ceramide transferase 2.4 1.1
D86322 Calmegin 9.2 2.5 X78926 HZF3 9.5 1.6
M63835 IgG Fc receptor I 3.2 0.9 Other functions
U70981 IL-13 3.4 0.7 M635346 Transferrin receptor 2.6 0.9
AF031167 IL-15 3.7 1.0 AB009672 ADAM 23 6.1 1.5
L17418 Complement receptor-1 4.3 0.9 M12272 ADH3 12.0 3.7
Y16645 MCP-2 5.3 2.6 J04027 Calcium-pumping ATase 2.0 1.1
M57230 gp130 3.7 0.8 U13616 Ankyrin 3 2.0 0.9
Integrins/Cytoskeleton U25997 Stanniocalcin 3.0 0.6
M12272 Integrin α2 6.1 1.1 AB002803 BACH1 2.1 0.7
D88460 N-WASP 13.2 2.2 M55153 Transglutaminase 5.4 4.5
M12272 Cadherin-13 17.1 2.2 L08850 AD amyloid 5.7 13.0
M68892 Integrin β7 2.0 1.0 M14218 Argininosuccinate lyase 2.4 0.9
AF032108 Integrin α7 2.3 1.2 U52112 NCAM L1 4.9 0.9
Human HSCs were stimulated with buffer or Ang II (10–8 M) for 24 hours in the presence or absence of DPI (10–6 M). Gene expression was assessed by microarray
analysis (see Methods). Experiments were repeated three times. Ang II upregulated 136 genes more than twofold with respect to cells treated with buffer. DPI pre-
treatment prevented upregulation of most of these genes. AThe table shows fold stimulation, with respect to untreated cells, of representative genes potentially
involved in liver fibrogenesis. Quantitative PCR confirmed the changes found in the microarray analysis in integrin α2, collagen α1(VI), and angiopoietin-1 (data
not shown). ADH3, alcohol dehydrogenase 3; ATF3, activating transcription factor 3; PAI-2, plasminogen activator inhibitor-2; FHF, FGF homologous factor.
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express the nonphagocytic NADPH oxidase.
Importantly, Ang II induced phosphoryla-
tion of p47phox through AT1 receptors in
activated HSCs (Figure 1d). We also assessed
whether ROS production by Ang II is associ-
ated with oxidative stress in HSCs. Ang II
increased lipid peroxidation in HSCs, as
demonstrated by induction of HNE-protein
adducts (Figure 1e). Moreover, Ang II
induced expression of heme oxygenase-1, a
sensitive marker of cellular oxidative stress
(40). This effect was inhibited by losartan and DPI, indi-
cating that oxidative stress is due to AT1-induced
NADPH oxidase activation. Finally, we investigated
whether Ang II also induces ROS formation in hepato-
cytes. Ang II (10–8 M) increased intracellular ROS levels
in primary rat hepatocytes and in HepG2 cells, a human
hepatoblastoma cell line (not shown). In both cell types,
ROS increase was slightly inhibited by DPI, suggesting
that Ang II–induced ROS production in hepatocytes is
mainly NADPH oxidase–independent.
Ang II activates MAPKs and AP-1 DNA-binding activity in
human HSCs in a redox-sensitive manner. We next investi-
gated the activation of intracellular signaling mole-
cules by Ang II. Ang II (10–8 M) markedly stimulated
the MAPK components ERK-2, p38 MAPK, and JNK, as
demonstrated by Western blotting of phosphorylated
proteins and by kinase assays (Figure 2a). This effect
was maximal between 5 and 15 minutes and was dose-
dependent (not shown). MAPK activation was mediat-
ed by AT1 and was blocked by DPI (10–6 M) and the
antioxidant NAC (10–4 M). Ang II also induced phos-
phorylation of AKT following a similar pattern. By con-
trast, Ang II did not stimulate STAT1/STAT3 phos-
phorylation, which was markedly activated by IFN-γ
(100 U/l) (Figure 2b). Moreover, Ang II (10–8 M)
increased AP-1 DNA binding in human HSCs (Figure
2c). This effect was prevented by losartan and blunted by
DPI. In contrast, Ang II (10–8 M) did not activate NF-κB
in human HSCs, as assessed by nuclear translocation of
p65, IκB degradation, IKK activity, and NF-κB reporter
gene transcription assay (data not shown).
DPI prevents Ang II–induced upregulation of genes involved
in wound-healing response in human HSCs. To further elu-
cidate the involvement of NADPH oxidase–derived
ROS in Ang II–induced effects in HSCs, we performed
gene-expression profiling using microarrays. Treat-
ment of human activated HSCs with ANG (10–8 M) for
24 hours increased the expression of genes implicated
Figure 3
Ang II induces biological effects in human HSCs in a
redox-sensitive manner. (a) Ang II (10–8 M) increases
DNA synthesis. This effect was prevented by losartan
(10–7 M), the ERK inhibitor PD98059 (5.10–6 M), the
PI3K inhibitor LY294002 (2.10–6 M), NAC (10–5 M), and
DPI (10–6 M), but not by the AT2 antagonist PD123319
(10–7 M). Results are expressed as mean ± SD of three
independent experiments. *P < 0.01 vs. buffer; ‡P < 0.01
vs. buffer + Ang II. (b) Ang II increased the number of
HSCs migrating through a modified Boyden chamber.
Pretreatment with losartan, LY294002, NAC, and DPI
inhibited this effect. Results are the mean ± SD from
three independent experiments. *P < 0.01 vs. buffer; 
‡P < 0.05 vs. buffer + Ang II. (c) In vitro wound-healing
assay. Ang II induced migration of cells into the wound.
This effect was inhibited by losartan and DPI. Images are
representative of three independent experiments. (d)
Ang II induces the secretion of proinflammatory
chemokines. Ang II increased secretion of IL-8 (white
bars) and MCP-1 (black bars). The base-line levels of
MCP-1 and IL-8 were 545 ± 43 pg/ml and 119 ± 23
pg/ml, respectively. Pretreatment with losartan, NAC,
and DPI attenuated this effect. Incubation with
PD98059, LY294002, the p38 MAPK inhibitor
SB203580 (10–6 M), and the JNK inhibitor SP600125
(20.10–6 M) attenuated cytokine secretion. Results are
the mean ± SD from six independent experiments. 
*P < 0.05 vs. buffer; ‡P < 0.05 vs. buffer + Ang II.
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tion induced by Ang II. We also explored the fibrogenic
effects of Ang II (10–8 M) in early-cultured HSCs (4 days
in culture). For this purpose, we used male rat HSCs to
circumvent the limitation on the availability of human
livers. Ang II (10–8 M) increased mRNA levels of pro-
collagen α1(I) and stimulated the secretion of collagen
I and bioactive TGF-β1 in rat HSCs (Figure 4). No
noticeable differences were observed in HSCs cultured
from either male or female rats (data not shown). These
effects were blocked by losartan and attenuated by DPI
(10–6 M) and NAC (10–4 M). Finally, we explored
whether NADPH oxidase regulates the spontaneous
HSC activation that occurs during prolonged culture
on plastic. Rat primary HSCs were cultured for 5 days
and then incubated in serum-free medium in the pres-
ence or absence of DPI (10–6 M) for an additional 48
hours. DPI treatment decreased smooth muscle α-actin
expression, cell proliferation, and collagen I secretion
by 40%, 25%, and 30%, respectively, compared with
untreated cells (data not shown).
HSCs from p47phox–/– mice show attenuated response to Ang II.
To further assess an involvement of NADPH oxidase in
Ang II–induced actions in HSCs, we studied HSCs iso-
lated from p47phox–/– mice. Ang II (10–8 M) increased
in the wound-healing response (Table 1). These genes
include ECM proteins (e.g., several collagens, matrilin
and sarcoglycan), growth factors and cytokines (e.g.,
HGF, angiopoietin-1, and keratinocyte growth factor),
proinflammatory cytokines (e.g., RANTES, IL-13, and
gp130), integrins, cell cycle and/or apoptosis regulato-
ry proteins (e.g., p27, mortalin, and MAD2), vasoactive
agonists (e.g., endothelin B receptor, adrenomedullin,
and thromboxane B2), and intracellular signaling fac-
tors (e.g., PPAR-γ and cathepsin S). Importantly, prein-
cubation of cells with DPI (10–6 M) attenuated the
upregulation of most of these genes, indicating that
NADPH oxidase–induced ROS mediate changes in
gene expression induced by Ang II in human HSCs.
Ang II stimulates proinflammatory and fibrogenic effects in
HSCs through NADPH oxidase activation. We next investi-
gated the biological effects of Ang II on human HSCs.
Cells were stimulated with 10–8 M of Ang II, a concen-
tration known to stimulate more than 70% of cultured
HSCs (12). Ang II (10–8 M) increased DNA synthesis, as
assessed by 3H-thymidine incorporation (Figure 3a).
This effect was prevented by losartan, by an ERK
inhibitor (PD98059), and by a PI3K/AKT pathway
inhibitor (LY294002), while a p38 MAPK inhibitor
(SB203580) and a JNK inhibitor (SP600125) had no
effect. Incubation of cells with DPI (10–6 M) or antiox-
idant treatment with NAC (10–4 M) inhibited Ang II–
induced DNA synthesis. Migration of HSCs was
assessed with a modified Boyden chamber and an in
vitro wound-healing assay. Ang II (10–8 M) induced
migration of human HSCs, as demonstrated by both
assays (Figure 3, b and c). This effect was blocked by
ERK and PI3K/AKT inhibitors and was attenuated by
DPI (10–6 M) and NAC (10–5 M). Moreover, Ang II
(10–8 M) stimulated the secretion of IL-8 and MCP-1
into the culture medium (Figure 3d). Inhibition of
ERK, JNK, and p38 MAPK, as well as DPI (10–6 M) and
NAC (10–4 M), inhibited the increased cytokine secre-
Figure 4
Ang II exerts profibrogenic actions in rat HSCs in a redox-sensitive
manner. Rat HSCs were cultured for 3 days and then stimulated for
24 hours with Ang II (10–8 M) in the presence or absence of losartan
(10–7 M), NAC (10–5 M), and DPI (10–6 M). (a) Steady-state mRNA
levels of procollagen α1(I) were assessed by RNase protection assay.
Data are expressed as the mean ratio between collagen α1(I) and
GAPDH mRNA levels of three independent experiments. *P < 0.01
vs. buffer; ‡P < 0.05 vs. Ang II. (b) Ang II stimulates collagen I secre-
tion by rat HSCs. Cell supernatants were collected, proteins precip-
itated, and collagen I content detected by Western blotting. Relative
expression is shown beneath each lane. The figure is representative
of three independent experiments. (c) Ang II increases the secretion
of bioactive TGF-β1 in rat HSCs. Cells were cultured for 3 days and
challenged with agonists for 20 hours. Cell medium was collected,
and total and bioactive TGF-β1 were measured by ELISA. Ang II 
(10–8 M) increased the secretion of bioactive TGF-β1 by 60%. Pre-
treatment with losartan, NAC, and DPI attenuated this effect.
Results are the mean ± SD from three independent experiments. 
*P < 0.01 vs. buffer; ‡P < 0.05 vs. Ang II.
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p47phox–/– mice compared with livers from p47phox+/+
mice following bile duct ligation (Figure 7, g–k). Alto-
gether, these results indicate than NADPH oxidase is an
important mediator in experimental liver fibrosis.
Discussion
Recent evidence indicates that the renin-angiotensin
system plays a role in liver fibrogenesis. The renin-
angiotensin system is locally expressed in injured liv-
ers, and Ang II inhibition attenuates experimental
intracellular ROS in HSCs isolated from WT C57BL/6
mice, while the ROS increase was blocked in p47phox–/–
HSCs (Figure 5a). Ang II (10–8 M) induced DNA synthe-
sis and cell migration in WT HSCs, as well as phospho-
rylation of ERK and c-Jun, while these effects were blunt-
ed in p47phox–/– HSCs (Figure 5, b–d). Collectively, these
results confirm that NADPH oxidase–derived ROS play
a major role in Ang II–induced actions in HSCs.
Liver fibrosis is markedly attenuated in p47phox–/– mice after
bile duct ligation. To assess the role of NADPH oxidase in
liver fibrosis, a model of secondary biliary fibrosis was
performed in p47phox–/– and p47phox+/+ mice. Following
bile duct ligation for 2 weeks, the degree of liver injury
was attenuated in p47phox–/– mice, as demonstrated by
lower liver/body weight ratio (Figure 6a), lower serum
levels of liver enzymes (Figure 6, b–d), and lower hepat-
ic concentration of inflammatory cytokines (Figure 6,
e–h). p47phox+/+ mice displayed severe septal fibrosis
with a marked disruption of the hepatic architecture
(Figure 7, a and c). Hepatic collagen content, as
assessed by morphometric analysis of Sirius red stain-
ing and by hepatic hydroxyproline, was increased as
expected in p47phox+/+ mice compared with sham-oper-
ated mice (Figure 7, e and f). In contrast, p47phox–/– mice
had only mild collagen deposition without formation
of bridging fibrosis (Figure 7, b and d). In addition, the
increase in hepatic collagen content in bile duct–ligat-
ed p47phox–/– mice was markedly attenuated compared
with that in p47phox+/+ mice (Figure 7, e and f). Moreover,
staining for smooth muscle α-actin, a marker of acti-
vated HSCs, and TGF-β1 was diminished in livers from
Figure 6
p47phox–/– mice show attenuated liver injury after bile duct ligation.
Effect of bile duct ligation for 2 weeks on liver/body weight ratio (a),
serum alanine aminotransferase (ALT) (b), serum aspartate amino-
transferase (AST) (c), bilirubin (d), and hepatic concentration of proin-
flammatory cytokines (TNF-α, IL-1β, MCP-1, and KC) (e–h). *P < 0.05
vs. sham operation; ‡P < 0.05 vs. bile duct ligation in p47phox–/–.
Figure 5
Effects of Ang II in WT and p47phox–/– mouse HSCs. HSCs were iso-
lated from C57BL/6 WT and p47phox–/– mice. Cells were studied after
14 days in culture (activated phenotype). (a) ROS production was
estimated in DCFDA-loaded mouse HSCs by a fluorometer at
485/535 nm. Ang II (10–8 M) increased intracellular ROS in WT
HSCs (open triangles), while the increase in ROS was attenuated in
p47phox–/– HSCs (filled circles). Cells exposed to buffer did not show
any increase in cell fluorescence (WT, filled triangles; p47phox–/–, open
circles). (b and c) Ang II (10–8 M) increases DNA synthesis (b) and
cell migration (c) in WT mouse HSCs, as assessed by 3H-thymidine
uptake and an in vitro migration assay in a modified Boyden cham-
ber, respectively. These effects were markedly attenuated in p47phox–/–
HSCs. *P < 0.05, WT buffer vs. WT Ang II. ‡P < 0.05, WT Ang II vs.
KO. (d) Effect of Ang II on phosphorylation of ERK and c-Jun, as
assessed by Western blot analysis. Ang II (10–8 M) stimulates ERK
and c-Jun phosphorylation in WT mouse HSCs, while both effects
were markedly blunted in p47phox–/– HSCs. Results are representative
of three independent experiments.
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liver fibrosis (6–10). Moreover, mice lacking AT1 recep-
tors are resistant to liver fibrosis after injury (L. Yang,
unpublished observations). Although the mechanisms
underlying the fibrogenic action of Ang II in the liver are
unknown, ROS may play a role. Increased ROS forma-
tion and oxidative stress are common findings during
liver injury, and antioxidants protect rats from devel-
oping liver fibrosis (20, 41, 42), suggesting a role for
ROS in the hepatic tissue-repair process. We recently
demonstrated that increased systemic Ang II induces
oxidative stress in the liver and activates HSCs (43).
Therefore, we propose a link between Ang II and excess
ROS production during liver fibrosis. NADPH oxidase
is a major source of ROS and mediates the actions of
Ang II in the vasculature (44, 45). We hypothesize that
NADPH oxidase–derived ROS play an important role in
liver fibrosis. We present evidence that Ang II induces
profibrogenic actions in activated HSCs, the main fibro-
genic cell in the injured liver. Moreover, NADPH oxi-
dase–derived ROS, by activating redox-sensitive intra-
cellular pathways, mediate Ang II–induced biological
effects in these cells. Finally, disruption of an active
NADPH oxidase protects mice from developing severe
fibrosis after bile duct ligation. These findings indicate
that a nonphagocytic NADPH oxidase is expressed in
HSCs and plays a role in liver fibrosis.
The current study explores the mechanisms by
which Ang II exerts fibrogenic effects in the injured
liver. Increased systemic Ang II levels induce oxidative
stress and vascular damage in the normal rat liver and
exacerbate fibrosis in rats with chronic injury (43).
Whether a local renin-angiotensin system also con-
tributes to hepatic fibrogenesis is unknown. Different
cell types can mediate the fibrogenic effect of Ang II in
the liver. Among them, we have focused on HSCs.
HSCs activate and accumulate in the injured liver,
secreting inflammatory cytokines and ECM proteins
and playing a key role in scar formation (46). We pre-
viously demonstrated that Ang II induces proliferation
of HSCs through its binding to AT1 receptors (12).
Here, we demonstrate that Ang II is a powerful
chemoattractant for activated HSCs. These two func-
tions of HSCs are believed to contribute to the accu-
mulation of myofibroblast-like cells in the injured liver
(2). Because Ang II is secreted by activated HSCs and
the renin-angiotensin system is overexpressed in bile
Figure 7
p47phox–/– mice are protected from liver fibrosis after bile duct ligation for 2 weeks. Representative photomicrographs of bile duct–ligated
liver sections processed for Masson’s trichrome (a and b) and Sirius red staining (c and d). p47phox+/+ mice developed extensive periportal
damage, necrotic areas around biliary tracts, bile duct proliferation, and bridging fibrosis (a and c). All these lesions were markedly atten-
uated in p47phox–/– mice (b and d). (e) Quantitation of the area stained for Sirius red. *P < 0.05 vs. p47phox–/– mice; ‡P < 0.05 vs. bile duct–lig-
ated WT mice. n = 5. (f) Hydroxyproline content in sham-operated and bile duct–ligated livers. *P < 0.05 vs. sham operation; ‡P < 0.05 vs.
bile duct ligation in p47phox–/–; n = 5. Immunodetection of smooth muscle α-actin in bile duct–ligated liver sections from p47phox+/+ (g) and
p47phox–/– mice (h) and TGF-β1 in bile duct–ligated liver sections from p47phox+/+ (i) and p47phox–/– mice (j). p47phox–/– mice showed decreased
staining for both smooth muscle α-actin and TGF-β1 compared with p47phox+/+ mice. Original magnifications were ×40, a–d; and ×100, g–j.
(k) Quantification of smooth muscle α-actin (α-SMA) content in liver tissues by Western blotting. Relative expression is shown beneath each
lane. The figure is representative of three independent experiments.
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duct–ligated livers (4, 12), we propose a role for Ang II
in the accumulation of HSCs at the areas of tissue
repair. Besides, Ang II induces the secretion of IL-8 and
MCP-1 by HSCs. These two chemokines are potential-
ly involved in the recruitment of inflammatory cells to
the liver (47). In vivo, systemic infusion of Ang II into
rats induces liver inflammation (43). These findings
indicate that Ang II exerts proinflammatory actions in
the liver. We also found that Ang II increases TGF-β1
expression and stimulates collagen I secretion in early-
cultured rat HSCs. This latter effect confirms pub-
lished data showing that the blockade of Ang II
inhibits TGF-β1 expression and collagen I deposition
in experimental liver fibrosis (7). Ang II also increases
ROS formation and stimulates ERK in primary hepa-
tocytes (48). It is unknown, however, whether Ang II
stimulates Kupffer cells and endothelial sinusoidal
cells, which play a major role in chronic liver diseases.
Intracellular ROS regulate key intracellular pathways
in vascular cell types (49, 50). Moreover, ROS mediate
the actions of Ang II in the kidney and the vasculature
(51). Based on these data, we hypothesize that ROS may
act as signaling molecules in HSCs mediating the
response to Ang II. We demonstrate that Ang II stimu-
lates AP-1 DNA binding, MAPKs, and AKT in HSCs. As
expected, Ang II regulates the expression of genes impli-
cated in the wound-healing process, including ECM pro-
teins, growth factors, cytokines, cell cycle and apoptosis
regulators, and vasoactive substances. Moreover, specif-
ic inhibitors of ERK and PI3K/AKT block Ang II–
induced proliferation, migration, and secretion of
chemokines. Inhibition and/or genetic ablation of a
functional NADPH oxidase and antioxidant treatment
blunt these effects, indicating that these pathways are
redox-sensitive. The functional role of NADPH oxi-
dase–derived ROS in Ang II–induced effects in HSCs is
supported by the finding that DPI strongly attenuates
upregulation of genes involved in fibrogenesis. Howev-
er, some of the genes potentially regulated by Ang II (e.g.,
IL-8) were not upregulated in the microarray experi-
ments, suggesting that Ang II may induce post-tran-
scriptional events in HSCs (e.g., increased IL-8 secretion).
The finding that p47phox is rapidly phosphorylated by
ANG and is required for ROS production indicates that
this subunit is required for enzymatic activity of NADPH
oxidase in HSCs. Pharmacological blockade of NADPH
oxidase with DPI blocks the Ang II–induced increase in
ROS, confirming that NADPH oxidase mediates the
increase in ROS after Ang II stimulation. In contrast,
DPI only slightly decreases ROS increase in hepatocytes,
indicating that Ang II–induced ROS production in hepa-
tocytes is mainly NADPH oxidase–independent. To our
knowledge, this is the first report showing that activat-
ed HSCs express functionally active NADPH oxidase.
Therefore, the HSC should no longer be viewed as a pas-
sive cell reacting to ROS and cytokines secreted by neigh-
boring cells (e.g., Kupffer cells, hepatocytes), but instead
as an active participant in the liver injury that produces
cytokines, chemokines, and ROS.
In the current study, we did not directly assess
whether the hepatic fibrogenic effect of Ang II in vivo is
mediated by NADPH oxidase. Instead, we assessed the
role of NADPH oxidase in liver fibrogenesis, by subject-
ing mice that lack p47phox to a well-characterized model
of secondary biliary cirrhosis. Compared with WT mice,
p47phox–/– mice showed a remarkable preservation of the
hepatic architecture and less fibrosis following bile duct
ligation. Expression of smooth muscle α-actin and
TGF-β1 was reduced in damaged livers from p47phox–/–
mice. Both findings suggest a role for NADPH oxidase
in key events in liver fibrosis. Moreover, hepatic proin-
flammatory cytokines were lower in p47phox–/– mice, sug-
gesting that NADPH oxidase participates in the inflam-
matory reaction that accompanies liver fibrosis. These
in vivo results indicate that NADPH oxidase plays a cru-
cial role in the hepatic wound-healing response to
injury. As we have demonstrated, nonphagocytic
NADPH oxidase is activated in HSCs during liver injury.
Chronic endogenous production of ROS by HSCs
would activate redox-sensitive pathways that lead to
inflammation and fibrogenesis. Of note, other hepatic
cell types can contribute to the fibrogenic role of
NADPH oxidase. In alcohol-induced liver injury, Kupf-
fer cells express phagocytic NADPH oxidase, which gen-
erates large amounts of ROS and mediates liver injury
(30). In addition, NADPH oxidase is activated in sinu-
soidal endothelial cells in alcohol-fed rats (52).
The results of the current study support the assump-
tion that ROS play an important role in the pathogen-
esis of liver fibrosis (13, 53). The most accepted theory
is that ROS derived from damaged hepatocytes, acti-
vated Kupffer cells, and infiltrating neutrophils stimu-
late HSCs in a paracrine manner (23, 54, 55). Exoge-
nous ROS would activate redox-sensitive intracellular
pathways in HSCs to increase collagen synthesis (14,
16). Here, we present evidence that HSCs are also an
important source of ROS in liver fibrosis. NADPH oxi-
dase is expressed in culture-activated HSCs and in
HSCs freshly isolated from cirrhotic livers, suggesting
that in vivo–activated HSCs may generate ROS. There-
fore, Ang II can generate endogenous ROS to exert its
fibrogenic effect on HSCs.
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